Stock listing

Hamburg:OCD1 Niagen Bioscience, Inc. Aktie

German listing (Hamburg) of Niagen Bioscience, Inc. · home listing NASDAQ:NAGE

Follow Niagen Bioscience, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:NAGE

$2.49 USD -0.09 (-3.5%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NAGE

Since Jul 6, 2026 -28.9% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$2.46 – $2.59 USDOct 16, 2026
Volume
555,766 sharesOct 16, 2026
Market value
$197.0M USDAt the close on Oct 16, 2026 · price × 79.13M shares outstanding
Niagen Bioscience, Inc. logo
Ticker
Hamburg:OCD1
Asset type
Stock
Exchange
Hamburg
Currency
EUR

What changed lately

Calls

Replays

  • Niagen Bioscience (NASDAQ:NAGE) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 4:30 PM ET

    Watch Transcript

  • Niagen Bioscience (NASDAQ:NAGE) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Niagen Bioscience (NASDAQ:NAGE) Q4 2025 Earnings Call

    Wed, Mar 04, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

Oct 15, 2026

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

Oct 8, 2026

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

Oct 6, 2026

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Oct 1, 2026

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

Sep 30, 2026

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

Sep 21, 2026

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Sep 17, 2026

Niagen Bioscience to Present at Canaccord Genuity’s Well Summit

Sep 10, 2026

Niagen Bioscience to Present at Longevity Investors Conference

Sep 2, 2026

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Aug 26, 2026

All Niagen Bioscience, Inc. news

Decks

Niagen Bioscience, Inc. on 6ix

News releases
49 in the last 12 months · 208 in all · newest Oct 15, 2026 · oldest 2020
Calls
30 calls with a replay · 30 with a transcript · latest Aug 4, 2026
Decks
58 decks · latest Aug 4, 2026

Where Niagen Bioscience, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NAGE · Home listingNASDAQUnited StatesUSD
gettex:OCD1gettexGermanyEUR
LS Exchange:A2AG5NLS ExchangeGermanyEUR
BOATS:NAGEBOATSUnited StatesUSD
Lang & Schwarz:A2AG5NLang & SchwarzGermanyEUR
Frankfurt:OCD1FrankfurtGermanyEUR
Dusseldorf:OCD1DusseldorfGermanyEUR
Hamburg:OCD1 · This pageHamburgGermanyEUR
Munich:OCD1MunichGermanyEUR
Stuttgart:OCD1StuttgartGermanyEUR
Tradegate:OCD1TradegateGermanyEUR

Log in to ask 6ix AI your own questions about Niagen Bioscience, Inc.